Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10484959 | Value in Health | 2014 | 8 Pages |
Abstract
LTHT is moderately cost-effective for patients with moderate to severe chronic obstructive pulmonary disease or bronchiectasis at a WTP threshold that is acceptable for public funding of medicines in New Zealand. These findings must be interpreted with caution because of the modest size of the clinical study, necessary lack of blinding in the clinical trial, and uncertainty in estimating health state utility from the SQRQ.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Richard J. BSc (Hons), MSc, PhD, Hans MSc, Harry MD, FRACP, FRCPE,